Profile data is unavailable for this security.
About the company
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
- Revenue in USD (TTM)16.35m
- Net income in USD-138.49m
- Incorporated2015
- Employees231.00
- LocationGritstone bio Inc5959 HORTON STREET, SUITE 300EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 871-6100
- Fax+1 (510) 597-1488
- Websitehttps://gritstonebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempest Therapeutics Inc | 0.00 | -29.49m | 77.23m | 17.00 | -- | 2.87 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| vTv Therapeutics Inc | 0.00 | -20.25m | 77.57m | 16.00 | -- | -- | -- | -- | -9.79 | -9.79 | 0.00 | -9.27 | 0.00 | -- | -- | 0.00 | -117.34 | -111.84 | -1,613.30 | -- | -- | -- | -- | -680.94 | -- | -- | -- | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 78.00m | 165.00 | -- | 4.62 | -- | 2.52 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 78.27m | 43.00 | -- | 5.73 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Chimerix Inc | 324.00k | -82.10m | 79.49m | 72.00 | -- | 0.4105 | -- | 245.33 | -0.9267 | -0.9267 | 0.0037 | 2.17 | 0.0013 | -- | 0.6207 | 4,500.00 | -33.36 | -30.45 | -36.22 | -34.09 | 100.00 | -- | -25,337.96 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 80.15m | 30.00 | -- | 5.18 | -- | 2.53 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| LifeVantage Corp | 210.95m | 2.96m | 80.30m | 248.00 | 26.91 | 2.94 | 12.15 | 0.3807 | 0.2319 | 0.2319 | 16.51 | 2.12 | 3.23 | 2.43 | 88.97 | 850,604.80 | 4.54 | 11.65 | 7.04 | 18.92 | 79.65 | 82.20 | 1.40 | 3.42 | 1.03 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Gritstone bio Inc | 16.35m | -138.49m | 80.97m | 231.00 | -- | 1.44 | -- | 4.95 | -1.55 | -1.55 | 0.1827 | 0.5313 | 0.0781 | -- | 36.53 | 70,761.91 | -66.18 | -48.08 | -77.72 | -55.18 | -- | -- | -847.24 | -573.71 | -- | -- | 0.4364 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 82.39m | 4.00 | -- | -- | -- | 147.74 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 83.20m | 10.00 | -- | 14.55 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | -- | -184.22 | -- | -404.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 83.53m | 225.00 | -- | -- | -- | 9.74 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 83.98m | 47.00 | -- | 3.15 | -- | 83.98 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Aclaris Therapeutics Inc | 31.25m | -88.48m | 84.40m | 91.00 | -- | 0.5367 | -- | 2.70 | -1.27 | -1.27 | 0.4477 | 2.22 | 0.1383 | -- | 79.92 | 343,395.60 | -39.15 | -47.29 | -44.34 | -53.87 | 42.14 | 44.00 | -283.15 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Aileron Therapeutics Inc | 0.00 | -15.73m | 84.86m | 15.00 | -- | 3.55 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Gritstone bio Inc's reporting currency: US Dollar USD
32.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2023 | 5.87m | 5.99% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 5.51m | 5.62% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.35m | 5.46% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.34m | 4.43% |
| Point72 Asset Management LPas of 31 Dec 2023 | 3.97m | 4.05% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.99m | 2.02% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.91m | 1.94% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.78m | 1.82% |
| Ensign Peak Advisors, Inc.as of 31 Dec 2023 | 797.88k | 0.81% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 731.92k | 0.75% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
